CLINICAL_TRIALS
ClinicalTrials.gov record update
Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04690231
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:45.427424+00:00
- Published At
- 2022-03-15T00:00:00+00:00
- Record Updated At
- 2022-03-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Effect of Drug", "Toxicity, Drug", "Secondary Resistance"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-03-15"- protocolSection.identificationModule.nctId
"NCT04690231"- protocolSection.identificationModule.officialTitle
"Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["NA"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.